Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.

Competing Interests: Declaration of Competing Interest The authors report the following conflicts of interest. The remaining authors report no conflicts of interest. Thomas J. Herzog: Honoraria/Reimbursement and Scientific advisory board AstraZeneca, Caris, Clovis, Genentech, GSK, Johnson and Johnson, Merck. Robert L. Coleman: Consulting, Grant, Honoraria/Reimbursement: Abbvie, Aravive, AstraZeneca, Clovis, Eisai, Genmab, GSK / Tesaro, Janssen, Merck, Oncomed, Mateon, Novocure, OncoQuest, Oncosec, Roche / Genentech, V-Foundation. Bradley J. Monk: Consulting and Honoraria/Reimbursement or Speakers' Bureau(s): Abbvie, Advaxis, Agenus, Amgen, Aravive, AstraZeneca, Asymmetric, Therapeutics, Boston Biomedical, ChemoCare, ChemoID, Circulogene, Clovis, Conjupro, Eisai, Geistlich, Genmab/Seattle Genetics: GOG Foundation, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson&Johnson, Laekna Health Care, Mateon (formally Oxigene), Merck, Mersana, Myriad, Nucana, Oncomed, Oncoquest, Oncosec, Perthera, Pfizer, Precision Oncology, Puma, Regeneron, Roche/Genentech, Samumed, Takeda, TESARO/GSK, VBL, Vigeo. John K. Chan: Consulting and Honoraria/Reimbursement or Speakers' Bureau(s): Acerta, Aravive, AstraZeneca, Biodesix, Clovis, Eisai, Janssen / J and J, Oxigene / Mateon, Roche / Genentech, Glaxosmithkline / Tesaro.